FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070894374> ?p ?o ?g. }

• W2070894374 endingPage "1135" @default.
• W2070894374 startingPage "1128" @default.
• W2070894374 abstract "Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin alpha1 (TA1), an immunomodulatory peptide, to the standard treatment regimen for hepatitis C to determine if combination therapy shows biological activity using outcome measures including normalization of alanine aminotransferase levels, histological activity, and viral load during treatment. We performed a randomized, double-blind, placebo-controlled trial to compare the biological activity of a combination TA1 and IFN with that seen for IFN alone in patients with chronic hepatitis C infection. One hundred nine patients were randomized for intention to treat and received 1.6 mg of TA1 subcutaneously twice weekly and 3 MU of IFN three times weekly; 3 MU of IFN three times weekly and placebo TA1; or placebo for both agents. All patients had chronic HCV infection with confirmation of chronic hepatitis on liver biopsy. Biochemical responders were followed up until alanine aminotransferase (ALT) levels became abnormal or for 26 weeks, and relapsers were retreated for 26 weeks in the same treatment arm. One hundred three patients completed treatment for 26 weeks, and six patients dropped out. The groups were similar with regard to sex, gender distribution, baseline histological activity index (HAI) score, risk factors, and viral titers. End-of-treatment biochemical response was seen in 37.1% of patients treated with combination therapy, 16.2% of patients treated with IFN alone, and 2.7% of untreated controls by intent-to-treat analysis (IFN/TA1 vs. IFN, chi2 = 4.05, P = .04). HCV RNA clearance was seen in 37.1% of IFN/TA1-treated patients and 18.9% of IFN-treated subjects. Mean HCV RNA titers were significantly lower than baseline at weeks 8, 16, and 24 after drug initiation among patients treated with IFN/TA1 but not in the other treatment arms. Histological improvement, as evidenced by a decrease in HAI of more than two points, occurred in the combination therapy arm more frequently than in comparison groups. Cumulative sustained biochemical responses were 14.2% and 8.1% in the IFN/TA1 and IFN arms, respectively, based on an intention-to-treat model. The combination of TA1 and standard IFN treatment for chronic hepatitis C showed evidence of biological activity at the completion of treatment by biochemical, histological, and virological outcome measures. Further research involving longer duration and varied dosing is needed." @default.
• W2070894374 created "2016-06-24" @default.
• W2070894374 creator A5008195189 @default.
• W2070894374 creator A5019395158 @default.
• W2070894374 creator A5023024608 @default.
• W2070894374 creator A5024470010 @default.
• W2070894374 creator A5051725555 @default.
• W2070894374 creator A5055495178 @default.
• W2070894374 creator A5061584208 @default.
• W2070894374 creator A5069023659 @default.
• W2070894374 creator A5076761358 @default.
• W2070894374 creator A5089299092 @default.
• W2070894374 creator A5090533069 @default.
• W2070894374 date "1998-04-01" @default.
• W2070894374 modified "2023-10-18" @default.
• W2070894374 title "Combination therapy with thymosin ?1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial" @default.
• W2070894374 cites W1511072029 @default.
• W2070894374 cites W1648420719 @default.
• W2070894374 cites W1968483985 @default.
• W2070894374 cites W1993262285 @default.
• W2070894374 cites W1998194069 @default.
• W2070894374 cites W2002088931 @default.
• W2070894374 cites W2002120703 @default.
• W2070894374 cites W2014754013 @default.
• W2070894374 cites W2019429013 @default.
• W2070894374 cites W2022593799 @default.
• W2070894374 cites W2031328832 @default.
• W2070894374 cites W2035212228 @default.
• W2070894374 cites W2061514638 @default.
• W2070894374 cites W2062814758 @default.
• W2070894374 cites W2066580123 @default.
• W2070894374 cites W2068507347 @default.
• W2070894374 cites W2069633422 @default.
• W2070894374 cites W2079377965 @default.
• W2070894374 cites W2085536840 @default.
• W2070894374 cites W2109499069 @default.
• W2070894374 cites W2115956200 @default.
• W2070894374 cites W2119600310 @default.
• W2070894374 cites W2164206153 @default.
• W2070894374 cites W2170516798 @default.
• W2070894374 cites W2334197314 @default.
• W2070894374 cites W2335968781 @default.
• W2070894374 cites W2336799715 @default.
• W2070894374 cites W4250840378 @default.
• W2070894374 doi "https://doi.org/10.1002/hep.510270430" @default.
• W2070894374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9537454" @default.
• W2070894374 hasPublicationYear "1998" @default.
• W2070894374 type Work @default.
• W2070894374 sameAs 2070894374 @default.
• W2070894374 citedByCount "89" @default.
• W2070894374 countsByYear W20708943742012 @default.
• W2070894374 countsByYear W20708943742013 @default.
• W2070894374 countsByYear W20708943742015 @default.
• W2070894374 countsByYear W20708943742017 @default.
• W2070894374 countsByYear W20708943742018 @default.
• W2070894374 countsByYear W20708943742019 @default.
• W2070894374 countsByYear W20708943742020 @default.
• W2070894374 crossrefType "journal-article" @default.
• W2070894374 hasAuthorship W2070894374A5008195189 @default.
• W2070894374 hasAuthorship W2070894374A5019395158 @default.
• W2070894374 hasAuthorship W2070894374A5023024608 @default.
• W2070894374 hasAuthorship W2070894374A5024470010 @default.
• W2070894374 hasAuthorship W2070894374A5051725555 @default.
• W2070894374 hasAuthorship W2070894374A5055495178 @default.
• W2070894374 hasAuthorship W2070894374A5061584208 @default.
• W2070894374 hasAuthorship W2070894374A5069023659 @default.
• W2070894374 hasAuthorship W2070894374A5076761358 @default.
• W2070894374 hasAuthorship W2070894374A5089299092 @default.
• W2070894374 hasAuthorship W2070894374A5090533069 @default.
• W2070894374 hasBestOaLocation W20708943741 @default.
• W2070894374 hasConcept C126322002 @default.
• W2070894374 hasConcept C142724271 @default.
• W2070894374 hasConcept C168563851 @default.
• W2070894374 hasConcept C203014093 @default.
• W2070894374 hasConcept C204787440 @default.
• W2070894374 hasConcept C27081682 @default.
• W2070894374 hasConcept C2776178377 @default.
• W2070894374 hasConcept C2776451592 @default.
• W2070894374 hasConcept C2776455275 @default.
• W2070894374 hasConcept C2777214474 @default.
• W2070894374 hasConcept C2781413609 @default.
• W2070894374 hasConcept C2909179924 @default.
• W2070894374 hasConcept C41260117 @default.
• W2070894374 hasConcept C71924100 @default.
• W2070894374 hasConcept C90924648 @default.
• W2070894374 hasConceptScore W2070894374C126322002 @default.
• W2070894374 hasConceptScore W2070894374C142724271 @default.
• W2070894374 hasConceptScore W2070894374C168563851 @default.
• W2070894374 hasConceptScore W2070894374C203014093 @default.
• W2070894374 hasConceptScore W2070894374C204787440 @default.
• W2070894374 hasConceptScore W2070894374C27081682 @default.
• W2070894374 hasConceptScore W2070894374C2776178377 @default.
• W2070894374 hasConceptScore W2070894374C2776451592 @default.
• W2070894374 hasConceptScore W2070894374C2776455275 @default.
• W2070894374 hasConceptScore W2070894374C2777214474 @default.
• W2070894374 hasConceptScore W2070894374C2781413609 @default.
• W2070894374 hasConceptScore W2070894374C2909179924 @default.
• W2070894374 hasConceptScore W2070894374C41260117 @default.

• next